Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the specialty pharmaceutical company will post earnings of $1.08 per share for the quarter, down from their previous estimate of $1.42. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical’s current full-year earnings is $6.38 per share.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. Collegium Pharmaceutical’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.77 EPS.

Several other brokerages have also recently commented on COLL. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Barclays dropped their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.40.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $32.50 on Monday. The company has a 50 day moving average of $36.81 and a 200 day moving average of $41.52. The stock has a market cap of $1.05 billion, a P/E ratio of 19.01 and a beta of 0.77. Collegium Pharmaceutical has a 12 month low of $26.16 and a 12 month high of $50.79. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the sale, the executive vice president owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the business. James Investment Research Inc. lifted its holdings in shares of Collegium Pharmaceutical by 19.7% in the 1st quarter. James Investment Research Inc. now owns 7,110 shares of the specialty pharmaceutical company’s stock worth $235,000 after acquiring an additional 1,170 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $3,185,000. Louisiana State Employees Retirement System bought a new stake in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $463,000. Ritholtz Wealth Management lifted its holdings in shares of Collegium Pharmaceutical by 35.1% in the 1st quarter. Ritholtz Wealth Management now owns 8,283 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 2,150 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Collegium Pharmaceutical by 284.4% in the 1st quarter. SG Americas Securities LLC now owns 66,397 shares of the specialty pharmaceutical company’s stock worth $2,196,000 after acquiring an additional 49,123 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.